"Toll-Like Receptor 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
| Descriptor ID |
D051217
|
| MeSH Number(s) |
D12.776.260.750 D12.776.543.750.705.910.500.900
|
| Concept/Terms |
Toll-Like Receptor 9- Toll-Like Receptor 9
- Toll Like Receptor 9
- TLR9 Receptor
- Receptor, TLR9
- TLR9 Protein
- CD289 Antigen
- Antigen, CD289
|
Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 9".
Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 9".
This graph shows the total number of publications written about "Toll-Like Receptor 9" by people in this website by year, and whether "Toll-Like Receptor 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Toll-Like Receptor 9" by people in Profiles.
-
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
-
Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021 03 18; 11(1):6267.
-
Determining Whether Agonist Density or Agonist Number Is More Important for Immune Activation via Micoparticle Based Assay. Front Immunol. 2020; 11:642.
-
Commentary: RAGE against the spleen. J Thorac Cardiovasc Surg. 2019 06; 157(6):2272-2273.
-
Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight. 2017 09 21; 2(18).
-
Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine. 2016 05 05; 34(21):2453-2459.
-
Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat Immunol. 2016 Feb; 17(2):196-203.
-
Gut microbiota elicits a protective immune response against malaria transmission. Cell. 2014 Dec 04; 159(6):1277-89.
-
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014 Nov 20; 41(5):830-42.
-
Hepatocyte-specific high-mobility group box 1 deletion worsens the injury in liver ischemia/reperfusion: a role for intracellular high-mobility group box 1 in cellular protection. Hepatology. 2014 May; 59(5):1984-1997.